Latest Tokyo Brief coverage on JCR Pharmaceuticals Co.,Ltd., tracking filings, financial news, and market signals from Japan.
TSE:4552
JCR Pharmaceuticals will keep manufacturing JR-141 while Italfarmaco takes over sales in the US, Europe and Latin America after approvals, with the upfront payment already in JCR's current-year forecast.
SanBio's newly launched cell therapy for chronic motor paralysis after traumatic brain injury, priced at ¥72.7mn a treatment, has generated no revenue and no dosed patients four months after its Japanese launch, and the company is now targeting only six cases by the fiscal year-end in January while its cash pile fell ¥2.34bn to ¥12.75bn over the same half-year.
JCR Pharmaceuticals will file for Japanese approval of givinostat, already sold for Duchenne muscular dystrophy in the US, EU and UK, using foreign trial data instead of a fresh domestic pivotal study, with a 2027 launch in view after talks with Japan's drug regulator.
Current holdings disclosed by tracked funds.